# Pain Management and the Opioid Epidemic Where are we today

Jeffrey Fudin, B.S., Pharm.D., FCCP, FASHP

Diplomate, Academy of Integrative Pain Management (AIPM)
President and Director, Scientific and Clinical Affairs, REMITIGATE LLC
Clinical Pharmacy Specialist & PGY2 Pain Residency Director; Stratton VA Medical Center (WOC)

Adjunct Associate Professor;
Albany College of Pharmacy & Health Sciences,
Western New England University College of Pharmacy, UCONN School of Pharmacy

# More specifically...

- •Where were we?
- •Where we are now?
- •How we got here (dispelling the myths)?
- Clarification of alternative facts

# Objectives

- 1. Interpret current opioid usage and outcomes data
- 2. Evaluate facts and myths associated with opioid usage and mortality
- Recognize at least 3 medical disorders of "epidemic proportion" other than opioid abuse that may involve addictive personality
- 4. Summarize pharmacist strategies to address the opioid epidemic and mitigate opioid risk

## Pre / Post Test #1

Nonmedical use of opioid analgesics from early 2000 to the mid-2000's have...

- A. increased approximatley 50%
- B. decreased approximately 50%
- C. remained the same
- D. have fluctuated up and down

## Pre / Post Test #2

Which of the following is true regarding morphine equivalent daily equivalent (MEDD) doses?

- A. There is general consensus of what constitutes an MEDD
- B. The Internet posted CDC calculator should be used to provide accurate morphine equivalents for methadone conversions
- C. Online opioid conversion calculators by states and federal agencies are generally consistent in terms of MEDD
- D. There is no general consensus on what constitutes an MEDD


# Two Types of Opioid Consumers

- 1. Opioid abuse disorder
  - Heroin
  - Carfentanil
  - RX opioids
  - Other
- 2. Legitimate opioid consumers (RX)
  - Long-term opioid therapy v. short-term acute pain
- 3. A combination of #1 and #2 above

### Myths about Opioid Addiction in the U.S.

- Opioid Abuse is dominated by the African-American community
- Increased opioid RX's are the cause of overdose deaths
- Addiction starts with teens using opioids

#### Total Opioid Death Rate by Race, 1999 – 2014



Krane E⊥using National Vital Statistics System of the CDC and Prevention Multiple Cause of Death files for 1999-2014.

Available at Pacing Event-ADE Deep Dive Opioid Use. Partnership for Patients and Communities, US Dept. HHS. https://www.healthcarecommunities.org/ResourceCenter/PartnershipforPatientsLibrary.aspx?CategoryId=836036&EntryId=110138

#### US Prescription Opioid-Related Deaths

- Approximately 16,000 deaths in 2013 from Rx opioids
- Approximately 9,000 deaths in 2013 from heroin
- According to the CDC:
  - ~85% unintentional ≈ 13,600 deaths
  - ~37 unintentional deaths/day
  - ~1 unintentional death every 40 minutes
- Children/infant deaths
  - ~3,300 in 2014 (down from 5,187 in 2004)

- Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep. 2015;64(1):32. National Vital Statistics Reports. 2015;64(2). www.cdc.gov/nchs/.
- Chen LH, et al. QuickStats: Rates of Deaths from Drug Poisoning and Drug Poisoning Involving Opioid Analgesics—United States, 1999–2013. MMWR Morb Mortal Wkly Rep 2015;64:32.
   (http://origin.glb.cdc.gov/mmwr/preview/mmwrhtml/mm6401a10.htm?s cid=mm6401a10 w)

# NSAID Mortality Putting things in perspective...

| Number of NSAID Deaths | 16,500                                                                      |
|------------------------|-----------------------------------------------------------------------------|
| Data Source            | Arthritis, Rheumatism, and Aging<br>Medical Information System<br>(ARAMIS)1 |
| Study Type             | 1999 observational study                                                    |


Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. *J Rheumatol.* 1999;26(Suppl 56):18-24.

#### **National Overdose Deaths**

National Institute on Drug Abuse




Number of Deaths from Prescription Opioid Pain Relievers (excluding non-methadone synthetics)



## National Overdose Deaths Number of Deaths from Heroin









# Opioid Analgesic Incidence Trends Nonmedical Use (NMU)

Persons ≥12 y/o *Initiating* NMU in Past Year (%)



http://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs2014/NSDUH-DetTabs2014.htm#tab7-44a National Survey on Drug and Health (NSDUH) Tables 7.44A&B

Figure 1. Past year initiation of heroin among individuals aged 12 or older, by age group: 2013




Source: SAMHSA, CBHSQ, National Survey on Drug Use and Health (NSDUH), 2013.

#### **National Overdose Deaths**

National Institute on Drug Abuse

Number of Deaths from Heroin and Non-Methadone Synthetics (captures illicit opioids)





Nonmethadone synthetics dominated by illicit fentanyl

#### **Alternative Facts**

Percentage of counties with changes in opioid prescribing — United States, 2010–2015

| Opioid prescribing measures        | Decrease (%) | Stable (%) | Increase (%) |
|------------------------------------|--------------|------------|--------------|
| MEDD per capita                    | 49.6         | 27.8       | 22.6         |
| Overall prescribing rate           | 46.5         | 33.8       | 19.6         |
| High-dose prescribing rate         | 86.5         | 6.7        | 6.9          |
| Average daily MME per prescription | 72.1         | 25.7       | 2.2          |

Guy GP, et al. MMWR Morb Mortal Wkly Rep. 2017;66:697–704.

#### Are deaths due to carfentanil?

- •2015 New Hampshire data:
  - ✓351 total opioid deaths
  - ✓ 28 died of heroin as a single-drug overdose
  - √ Fentanyl was a factor in 253 of the overdose deaths!

Costantini C, et al. "Death by Fentanyl". Documentary, aired December 3, 2016. (NH State Medical Examiner data)

- •2017 New Hampshire data (January 1-April 13, 2017):
  - √0 deaths from heroin alone
  - √ 18 deaths due to fentanyl
  - √ 2 deaths from a heroin-fentanyl combination
  - √86 deaths pending toxicology reports

Leclerc C. More people now dying from fentanyl than heroin in New Hampshire. WMUR on Demand. April 13, 2017.

# Substance Abuse is Complex Political rhetoric attempts to simplify the issues...

- Genetic
- Psychiatric
- Social
- Environmental
- Economic

### Medical Problems Involving Addiction

- Diabetes
- Obesity
- Lung Cancer
- •GERD<sup>1</sup>

1. Yoshikawa I, et al. Long-term treatment with proton pump inhibitor is associated with undesired weight gain. World J Gastroenterol. 2009; 15(38): 4794-4798.

#### Does formulation selection matter?



**Fentanyl Patch** 



**Fentanyl TIRF** 

### Addiction (ASAM-short)

- •A primary, chronic disease involving brain dysfunction which encompassing reward, motivation, memory and related circuitry.
  - •Includes biological, psychological, social and spiritual manifestations.
  - Compulsive reward seeking
    - relief by substance use and other behaviors
    - •Examples?

https://www.asam.org/quality-practice/definition-of-addiction

### Addiction is not Simply a Disease of Exposure

Exposure is necessary but not sufficient

- ✓ Exposure to drug
- ✓ Vulnerable person
- ✓ Vulnerable time

Savage SR, Kirsh KL, Passik SD. Challenges in using opioids to treat pain in persons with substance use disorders. Addiction science & clinical practice. 2008 Jun;4(2):4.

### Could this have ended badly?

#### Newsflash, April 2013 Louisville Player Shatters Leg During Elite 8 Game



# Louisville athlete Kevin Ware, 2013

- ✓ Exposure to drug
- √Vulnerable person
- √Vulnerable time

Aleccia J. Gruesome basketball injury for Ware a 'freak accident,' doc says. NBC News. Apr 01, 2013.

http://www.wrcbtv.com/story/21842623/gruesome-basketball-injury-for-ware-a-freak-accident-doc-says

| Risk<br>Assessme<br>nt Tools | Questi<br>on<br>Format<br>s | Indications                                                                                                          | Advantag<br>es                                                                                                        | Disadva<br>ntages                                                                                                    | Scoring                            | Validated                                                                                                                   |                                                                               |
|------------------------------|-----------------------------|----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| SOAPP <sup>1</sup>           | 5, 14, 24                   | 1° Care, Assess for high abuse risk, suitability for long term opioid tx, preferable to ORT in high-risk populations | Best<br>psychometrics,<br>less<br>susceptible to<br>deception, 5-10<br>minutes                                        | Dependent<br>on patient<br>reporting,<br>Copyrighte<br>d                                                             | Numeric,<br>simple to<br>interpret | Yes, 14 quest<br>ion studied in<br>396 pts                                                                                  | Strateg                                                                       |
| SOAPP-R <sup>2</sup>         | 24                          | Primary Care                                                                                                         | 5 minutes,<br>Cross-<br>validated, Less<br>susceptible to<br>overt<br>deception c/t<br>SOAPP                          | Less<br>sensitive<br>and less<br>specific<br>than<br>SOAPP                                                           | Numeric,<br>simple to<br>interpret | Yes, 283 pts                                                                                                                | Strateg<br>Assess                                                             |
| ORT <sup>3</sup>             | 5                           | Categorizes<br>patients as low<br>risk, moderate<br>risk, and high<br>risk                                           | Less than 1<br>minute, simple<br>scoring, high<br>sensitivity &<br>specificity<br>when<br>stratifying<br>patients     | 1 question<br>in the ORT<br>is limited by<br>patient's<br>knowledge<br>of family<br>history of<br>substance<br>abuse | Numeric,<br>simple to<br>interpret | Yes, (male and female), Preliminary Validation in 185 patients at 1 pain clinic, high degree of sensitivity and specificity | 1. J Pain Sympto<br>2. J Pain. 2008 A<br>3. Pain Med 2009<br>4. J Pain 2006;7 |
| DIRE <sup>4</sup>            | 7, by pt<br>interview       | risk of opioid<br>abuse and<br>suitability of<br>candidates for<br>long term opioid<br>therapy                       | 2 minutes,<br>score<br>correlates well<br>with patient's<br>compliance&<br>efficacy of long<br>term opioid<br>therapy | Prospective<br>validation<br>needed                                                                                  | Numeric,<br>simple to<br>interpret | ?,<br>Retrospective<br>validation<br>only of 61 pts<br>over 38<br>months                                                    |                                                                               |

### gies: Abuse Risk

- ptom Manage 2006;32:287–93 3 April; 9 (4): 360-372 005;6:432–42 ;7:671–81

|                   | <b>A</b> :   | 1 11 41                                                                                                    | A 1 4                                                                                                         | B: 1                                                                                                                                                | O                                                                                          | M-P 1-4- 1                                                                                                                   |
|-------------------|--------------|------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|
| Opioid            | Question     | Indication                                                                                                 | Advantage                                                                                                     | Disadva                                                                                                                                             | Scoring                                                                                    | Validated                                                                                                                    |
| Misuse            | Formats      | S                                                                                                          | S                                                                                                             | ntages                                                                                                                                              |                                                                                            |                                                                                                                              |
| Tools             |              |                                                                                                            |                                                                                                               |                                                                                                                                                     |                                                                                            |                                                                                                                              |
| PADT <sup>5</sup> | N/A          | To streamline the assessment of outcomes in patients with chronic pain, 2 sided chart note based on 4-A's* | 5 minutes,<br>Documents<br>progress over<br>time,<br>Complements a<br>comprehensive<br>clinical<br>evaluation | Not intended<br>to be<br>predictive of<br>drug-<br>seeking<br>behavior or<br>predict<br>positive or<br>negative<br>outcomes to<br>opioid<br>therapy | N/A                                                                                        | Further studies<br>needed to<br>confirm the<br>reliability and<br>validity,<br>Studied in 388<br>patients by 27<br>clinician |
| COMM <sub>6</sub> | 17           | To assess aberrant medication related behaviors of chronic pain patients                                   | 10 minutes,<br>Useful in<br>assessing &<br>reassessing<br>adherence to<br>opioid RX(s)                        | Long term<br>reliability is<br>unknown                                                                                                              | Numeric                                                                                    | 222 pts, Long<br>term reliability<br>is unknown,<br>Validated in<br>small study,<br>needs to be<br>replicated                |
| ABC <sup>7</sup>  | 20 questions | Ongoing clinical assessment of chronic pain patients on opioid therapies                                   | Concise and<br>easy to score<br>Studied in the<br>VA setting                                                  | Needs<br>validation in<br>non-VA<br>setting.                                                                                                        | Score of ≥3<br>indicates<br>possible<br>inappropriate<br>opioid based<br>on Y/N<br>answers | Studied 136<br>veterans in a<br>multidisciplina<br>ry VA Chronic<br>Pain Clinic                                              |


#### Strategies: Assess Misuse Risk

- 5. Clin Ther 2004; 26:552–61
- 6. Pain. 2007 July; 130(1-2):144-156
- 7. J Pain Symptom Manage 2006;32:342-351

# What should pharmacist not do...

- 1. Perpetuate false information and rhetoric
- 2. Deny prescriptions based solely on MEDD
- 3. Assume that MEDD is accurate (more to come...)
- 4. Avoid counseling when patient "forfeits" it
- 5. Prejudge patients receiving chronic opioid therapy
- 6. Dispense opioids combined with sedativehypnotics without carefully checking the reasons with patient and prescriber

#### (+/-) % Variation (Compared to Manual Calculation)



Shaw K, Fudin J. Evaluation and Comparison of Online Equianalgesic Opioid Dose Conversion Calculators. Practical Pain Management. 2013 August; 13(7):61-66. PPM 2013

## CDC Advert for CDC Online Opioid Calculator

#### Injury Prevention & Control: Opioid Overdose



CDC > Opioid Overdose > CDC Guideline for Prescribing Opioids for Chronic Pain > Guideline Resources

#### Guideline Resources: CDC Opioid Guideline Mobile App





CDC's new Opioid Guideline App is designed to help providers apply the recommendations of CDC's Guideline for Prescribing Opioids for Chronic Pain into clinical practice by putting the entire guideline, tools, and resources in the palm of their hand. Managing chronic pain is complex, but accessing prescribing guidance has never been easier.

The application includes a Morphine Milligram Equivalent (MME) calculator\*, summaries of key recommendations and a link to the full Guideline, and an interactive motivational interviewing feature to help providers practice effective communications skills and prescribe with confidence.

#### Free Download

The new CDC Opioid Guideline App is now available for free download on Google Play 2 (Android devices) and in the Apple Store ☑ (iOS devices).








#### CDC Opioid Guideline App: Prescribe with Confidence



Opioid Prescribing Guideline Mobile App



#### CDC Calculator lacks accuracy with methadone conversion!



#### Calculating morphine milligram equivalents (MME)

| OPIOID (doses in mg/day except where noted) | CONVERSION FACTOR |  |  |
|---------------------------------------------|-------------------|--|--|
| Codeine                                     | 0.15              |  |  |
| Fentanyl transdermal (in mcg/hr)            | 2.4               |  |  |
| Hydrocodone                                 | 1                 |  |  |
| Hydromorphone                               | 4                 |  |  |
| Methadone                                   |                   |  |  |
| 1-20 mg/day                                 | 4                 |  |  |
| 21-40 mg/day                                | 8                 |  |  |
| 41-60 mg/day                                | 10                |  |  |
| ≥ 61-80 mg/day                              | 12                |  |  |
| Morphine                                    | 1                 |  |  |
| Oxycodone                                   | 1.5               |  |  |
| Oxymorphone                                 | 3                 |  |  |

These dose conversions are estimated and cannot account for all individual differences in genetics and pharmacokinetics.

https://www.cdc.gov/drugoverdose/pdf/calculating\_total\_daily\_dose-a.pdf

### An Actual Example from CDC Smart Phone App

| Guideline Resources: CDC Opioid Guideline Mobile App |                           |  |  |
|------------------------------------------------------|---------------------------|--|--|
| "Morphine Equivalent" (mg)                           | Methadone Daily Dose (mg) |  |  |
| 80                                                   | 20                        |  |  |
| 168                                                  | 21                        |  |  |
| 320                                                  | 40                        |  |  |
| 410                                                  | 41                        |  |  |

https://www.cdc.gov/drugoverdose/prescribing/app.html

# Conclusion

What should we do?

## Conclusions / What should pharmacists do?

- 1. Check PDMP
- 2. Participate & promote educational programs for patients, pharmacists, and other clinicians
- 3. Be a team player with prescribers
- 4. In an ideal world
  - ✓ Assess risk for OIRD, abuse, and misuse prior to discharge and when dispensing RX in community
- 5. Treat each patient with "individualized" approach
- 6. Evaluate for and provide naloxone for in-home use

# Pre / Post Test #1

Nonmedical use of opioid analgesics from early 2000 to the mid-2000's have...

- A. increased approximately 50%
- B. decreased approximately 50%
- C. remained the same
- D. have fluctuated up and down

# Pre / Post Test #2

Which of the following is true regarding morphine equivalent daily equivalent (MEDD) doses?

- A. There is general consensus of what constitutes an MEDD
- B. The Internet posted CDC calculator should be used to provide accurate morphine equivalents for methadone conversions
- C. Online opioid conversion calculators by states and federal agencies are generally consistent in terms of MEDD
- D. There is no general consensus on what constitutes an MEDD

# Questions?